Novel topoisomerase inhibitors: microbiological characterisation and in vivo efficacy of pyrimidines.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  International Journal of Antimicrobial Agents

• Publication date

  2013-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ijantimicag.2012.12.001PMID 23305654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents

  2011cited by this paper
• Directed-Mutagenesis and Deletion Generated through an Improved Overlapping-Extension PCR Based Procedure

  2007cited by this paper
• High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry.

  2006cited by this paper
• In Vitro Characterization of the Antibacterial Spectrum of Novel Bacterial Type II Topoisomerase Inhibitors of the Aminobenzimidazole Class

  2006cited by this paper
• Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard

  2006cited by this paper
• Introduction: antibiotic resistance.

  2005cited by this paper
• The ATP-binding site of type II topoisomerases as a target for antibacterial drugs.

  2003influential reference
• Roles of Topoisomerases in Maintaining Steady-state DNA Supercoiling in Escherichia coli *

  2000cited by this paper
• Multiple Mechanisms of Action for Inhibitors of Histidine Protein Kinases from Bacterial Two-Component Systems

  1999cited by this paper
• An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae.

  1995cited by this paper
• Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease.

  1991cited by this paper
• The pharmacokinetics of Norpace.

  1975cited by this paper

• Supramolecular interactions, electronic properties and docking studies of Bis (2-amino-4,6-dimethylaminopyrimidin-1-ium gallate) Trihydrate: Implications for Cancer cell interactions

  2025cites this paper
• Exploring the antibiofilm efficacy of pyrimidines against Vibrio parahaemolyticus, mechanisms and their potential food processing applications

  2024cites this paper
• Elucidating specific interactions for designing novel pyrrolamide derivatives as potential GyrB inhibitors based on ab initio fragment molecular orbital calculations

  2023cites this paper
• Single-molecule dynamics of DNA gyrase in evolutionarily distant bacteria Mycobacterium tuberculosis and Escherichia coli

  2023cites this paper
• Identification of Potent DNA Gyrase Inhibitors Active against Mycobacterium tuberculosis

  2022cites this paper
• Facilitating Compound Entry as a Means to Discover Antibiotics for Gram-Negative Bacteria.

  2021cites this paper
• The search for novel treatment strategies for Streptococcus pneumoniae infections

  2021cites this paper
• Ligand-based pharmacophore modelling, in silico virtual screening, molecular docking and molecular dynamic simulation study to identify novel Francisella tularensis ParE inhibitors

  2020cites this paper
• Synthesis, crystal structure, and ADME prediction studies of novel imidazopyrimidines as antibacterial and cytotoxic agents

  2020cites this paper
• ATP-competitive DNA gyrase and topoisomerase IV inhibitors as antibacterial agents

  2019cites this paper
• Novel organophosphorus aminopyrimidines as unique structural DNA-targeting membrane active inhibitors towards drug-resistant methicillin-resistant Staphylococcus aureus.

  2018cites this paper
• Molecular insights on analogs of imidazo[1,2-a]pyridine, azaindole, and pyridylurea towards ParE using pharmacophore modeling, molecular docking, and dynamic simulation

  2017cites this paper
• New N-phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATPase inhibitors of DNA gyrase.

  2016cites this paper
• Identifying selective ligands for glutaredoxin proteins with fragment based drug design approach and optimization of the bacterial selective hits

  2016cites this paper
• New Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development.

  2016cites this paper
• Strukturbasierte Leitstruktursuche ATP-kompetitiver Inhibitoren der Gyrase Untereinheit B

  2015cites this paper
• A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV.

  2015cites this paper
• Mutant Alleles of lptD Increase the Permeability of Pseudomonas aeruginosa and Define Determinants of Intrinsic Resistance to Antibiotics

  2015cites this paper
• Assays, Surrogates, and Alternative Technologies for a TB Lead Identification Program Targeting DNA Gyrase ATPase

  2015cites this paper
• ESKAPEing the labyrinth of antibacterial discovery

  2015cites this paper
• Chapter 34 – Design of Antibacterial Agents

  2015cites this paper
• Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism.

  2014cites this paper
• Applications of structure-based design to antibacterial drug discovery.

  2014cites this paper
• Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.

  2014cites this paper
• Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).

  2014cites this paper
• Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.

  2014cites this paper
• A Novel High-Throughput Cell-Based Assay Aimed at Identifying Inhibitors of DNA Metabolism in Bacteria

  2014cites this paper
• Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase.

  2014cites this paper
• Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.

  2013cites this paper
• Prospects for developing new antibacterials targeting bacterial type IIA topoisomerases.

  2013cites this paper